Alethia BioTherapeutics Inc.

Swiss biotech firm Idorsia Pharmaceuticals is set to learn this week whether its insomnia drug daridorexant is on track for EU-wide approval. The drug was authorized as Quviviq in the US in January.

Manufacturing inspections remain a sore spot for new drug and biologic applications, both because the COVID-19 pandemic still impeding the ability of inspectors to travel to facilities and because ins

Shareholders remain unhappy with Aerie Pharmaceuticals, Inc. ’s attempt to spin a failed Phase IIb study for its TRMP8 agonist AR-11512 in dry eye disease as a success. But since multiple endpoints w

In a world without the COVID-19 pandemic, the FDA’s total of more than 50 novel drugs and biologics approved in 2020 would be another notable year in a string of the most productive years in modern ag